Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for ZAP70 Deficiency - PubMed (original) (raw)

Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for ZAP70 Deficiency

Geoffrey D E Cuvelier et al. J Clin Immunol. 2016 Oct.

Abstract

ZAP70 deficiency is a rare T + B + NK+ combined immunodeficiency with limited outcome data to help guide decisions around hematopoietic stem cell transplant (HSCT). We sought to understand the long-term clinical and immunologic outcomes of both conditioned and unconditioned HSCT for ZAP70 deficiency following transplant from a variety of graft sources. We performed a retrospective, single center review of all cases of HSCT for genetically confirmed ZAP70 deficiency since 1992. At a median of 13.5-year post-HSCT, 8/8 (100 %) patients are alive. Three received unconditioned bone marrow transplants from human leukocyte antigen (HLA)-matched siblings and achieved stable mixed donor-recipient T cell chimerism but low B cell (4-9 %) and absent to near-absent myeloid donor engraftment. Despite this, all three have normal immunoglobulin levels, have developed specific protective antibody responses to post-HSCT vaccinations, and have discontinued immunoglobulin replacement. Five patients received myeloablative conditioning (three T cell-depleted haploidentical and two unrelated cord blood) and have full donor chimerism for T and B cells and myeloid lineages. One patient experienced primary graft failure after serotherapy only. CD8 T cell count is normal in 5/8, high in 1/8, and low in 2/8. Infectious complications in 5/5 and autoimmune thrombocytopenia in one patient resolved post-HSCT. Mitogen proliferation to phytohemagglutinin was normal after HSCT in 8/8 patients. In total, seven have discontinued immunoglobulin replacement. In conclusion, HSCT using a variety of graft sources and approaches, including unconditioned matched sibling donor transplant, is a life-saving therapy for ZAP70 deficiency, providing excellent long-term immune function and resolution of clinical problems.

Keywords: T+ SCID; ZAP70 deficiency; atypical SCID; hematopoietic stem cell transplant; leaky SCID.

PubMed Disclaimer

References

    1. Bone Marrow Transplant. 2000 Mar;25(6):613-21 -PubMed
    1. Clin Immunol. 2009 Oct;133(1):95-107 -PubMed
    1. N Engl J Med. 1999 Feb 18;340(7):508-16 -PubMed
    1. Clin Immunol. 2014 Jul;153(1):209-10 -PubMed
    1. J Clin Immunol. 2013 Jan;33(1):96-110 -PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources